SCHEMBL2901554

SCHEMBL2901554

COc1cnc(N)c(OC)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FYN P06241 9/20 0.45
ALDH1A1 P00352 3/20 0.45
CYP3A4 P08684 1/20 0.45
CA12 O43570 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
CA7 P43166 1/20 0.41
CA9 Q16790 1/20 0.41
CA14 Q9ULX7 1/20 0.41
GAA P10253 1/20 0.41
MAPK1 P28482 1/20 0.41
HTT P42858 1/20 0.41
GFER P55789 1/20 0.41
MAPT P10636 2/20 0.41
MEN1 O00255 1/20 0.41
THRB P10828 1/20 0.41
KMT2A Q03164 1/20 0.41
NOS3 P29474 1/20 0.41
NOS1 P29475 1/20 0.41
NOS2 P35228 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23641248 0.81 PIK3CA (0.38) FYNALDH1A1CYP3A4TLR8P2RX3
SCHEMBL27314054 0.81 MAP3K12 (0.42)
SCHEMBL30031982 0.81 PIK3CA (0.38) FYNALDH1A1CYP3A4TLR8P2RX3
SCHEMBL2957518 0.80 ALDH1A1 (0.42) FYNALDH1A1CYP3A4GAAMAPT
SCHEMBL2616551 0.80 FYN (0.44) FYNALDH1A1GAAMAPK1HTT
SCHEMBL28053269 0.80 ALDH1A1 (0.51) FYNALDH1A1CYP3A4MAPK1MEN1
SCHEMBL16416412 0.79 PIK3CA (0.42) FYNALDH1A1CHEK2MAPKAPK2
SCHEMBL30723495 0.79 SCN9A (0.38) FYN
SCHEMBL23641518 0.79 SCN9A (0.38) FYN
SCHEMBL23948543 0.78 NOS3 (0.56) FYNALDH1A1NOS3NOS1NOS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4615839-A1 INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE, COMPOSITIONS, AND METHODS OF USE Bristol-Myers Squibb Company (US) 2025-09-17 EP disclosed
CN-120152973-A Protein tyrosine phosphatase inhibitors, compositions, and methods of use 百时美施贵宝公司 2025-06-13 CN disclosed
US-12071404-B2 Aza (indole)-, benzothiophene-, and benzofuran-3-sulfonamides UCB PHARMA GMBH (DE) 2024-08-27 US disclosed
US-20240180886-A1 INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE, COMPOSITIONS, AND METHODS OF USE BRISTOL-MYERS SQUIBB COMPANY (US) 2024-06-06 US disclosed
WO-2024102794-A1 INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE, COMPOSITIONS, AND METHODS OF USE BRISTOL-MYERS SQUIBB COMPANY (US) 2024-05-16 WO disclosed
US-11820746-B2 Aza (indole)-, benzothiophene-, and benzofuran-3-sulfonamides UCB PHARMA GMBH (DE) 2023-11-21 US disclosed
US-11820746-B2 Aza (indole)-, benzothiophene-, and benzofuran-3-sulfonamides UCB PHARMA GMBH (DE) 2023-11-21 US disclosed
US-11820746-B2 Aza (indole)-, benzothiophene-, and benzofuran-3-sulfonamides UCB PHARMA GMBH (DE) 2023-11-21 US disclosed
US-20230348384-A1 Aza (Indole)-, Benzothiophene-, And Benzofuran-3-Sulfonamides UCB PHARMA GMBH (DE) 2023-11-02 US disclosed
US-20230348384-A1 Aza (Indole)-, Benzothiophene-, And Benzofuran-3-Sulfonamides UCB PHARMA GMBH (DE) 2023-11-02 US disclosed
US-11345662-B2 Aza (indole)-, benzothiophene-, and benzofuran-3-sulfonamides UCB PHARMA GMBH (DE) 2022-05-31 US disclosed
US-11345662-B2 Aza (indole)-, benzothiophene-, and benzofuran-3-sulfonamides UCB PHARMA GMBH (DE) 2022-05-31 US disclosed
US-20220127227-A1 Aza (Indole)-, Benzothiophene-, And Benzofuran-3-Sulfonamides UCB PHARMA GMBH (DE) 2022-04-28 US disclosed
US-20220127227-A1 Aza (Indole)-, Benzothiophene-, And Benzofuran-3-Sulfonamides UCB PHARMA GMBH (DE) 2022-04-28 US disclosed
US-20190345104-A1 Aza (Indole)-, Benzothiophene-, And Benzofuran-3-Sulfonamides UCB PHARMA GMBH (DE) 2019-11-14 US disclosed
CN-108291306-A Plating bath composition and method for electroless plating of palladium 埃托特克德国有限公司 2018-07-17 CN disclosed
WO-2018122232-A1 (AZA)INDOLE-, BENZOTHIOPHENE-, AND BENZOFURAN-3-SULFONAMIDES UCB PHARMA GMBH (DE) 2018-07-05 WO disclosed
US-20100298324-A1 Prolyl Hydroxylase Inhibitors SMITH KLINE BEECHAM CORPORATION (US) 2010-11-25 US disclosed
EP-2240178-A1 PROLYL HYDROXYLASE INHIBITORS GlaxoSmithKline LLC (US) 2010-10-20 EP disclosed
WO-2009086044-A1 PROLYL HYDROXYLASE INHIBITORS SMITH KLINE BEECHAM CORPORATION (US) 2009-07-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100298324-A1 Prolyl Hydroxylase Inhibitors HIF1AN, EGLN3, EGLN2 FYN 4813/4885ALDH1A1 204/4885CYP3A4 603/4885
US-20220127227-A1 Aza (Indole)-, Benzothiophene-, And Benzofuran-3-Sulfonamides GPR17, GPR18, GPR27 FYN 3268/4885ALDH1A1 1065/4885CYP3A4 2597/4885
US-11345662-B2 Aza (indole)-, benzothiophene-, and benzofuran-3-sulfonamides GPR17, GPR18, GPR27 FYN 3268/4885ALDH1A1 1065/4885CYP3A4 2597/4885
US-11820746-B2 Aza (indole)-, benzothiophene-, and benzofuran-3-sulfonamides GPR17, GPR18, GPR27 FYN 3268/4885ALDH1A1 1065/4885CYP3A4 2597/4885
US-20230348384-A1 Aza (Indole)-, Benzothiophene-, And Benzofuran-3-Sulfonamides GPR17, GPR18, GPR27 FYN 3268/4885ALDH1A1 1065/4885CYP3A4 2597/4885
US-20240180886-A1 INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE, COMPOSITIONS, AND METHODS OF USE PTPN2, PTPN22, PTPN1 FYN 81/4885ALDH1A1 3561/4885CYP3A4 3555/4885
US-12071404-B2 Aza (indole)-, benzothiophene-, and benzofuran-3-sulfonamides GPR17, GPR18, GPR27 FYN 3268/4885ALDH1A1 1065/4885CYP3A4 2597/4885
US-20190345104-A1 Aza (Indole)-, Benzothiophene-, And Benzofuran-3-Sulfonamides GPR17, GPR18, GPR27 FYN 3268/4885ALDH1A1 1065/4885CYP3A4 2597/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.